Background Respiratory failure and death are the leading causes of severe Coronavirus
disease 2019 (COVID‐19). Hyper‐inflammation and cytokine storm cause lung damage …

Background Pneumonia is the most frequent complication of COVID-19, due to an aberrant
host immune response that is associated with an acute respiratory distress syndrome, and …

Background: Tocilizumab has shown promising effects in the management of coronavirus
disease 2019 (COVID-19) patients. Nebulized tocilizumab might reduce this inflammation …

Background We sought to evaluate the effect of tocilizumab (TCB), a recombinant
humanized monoclonal antibody against soluble interleukin‐6 receptors, in patients …

Background The first case of Infection with severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) was diagnosed in Wuhan, China in 2019. In the first half of 2020, this disease …

To the Editor, A recent report in this journal described the severe nature and potentially fatal
outcome of COVID-19 [1]. The coronavirus disease, identified as COVID-19, has rapidly …

Introduction Since the beginning of the COVID-19 pandemic, the repurposing of medicines
has been pursued to find interventions effective in preventing fatal outcome of the disease …

Background Tocilizumab (TCZ), an interleukin-6 receptor antibody, has previously been
used for treating patients with the coronavirus disease 2019 (COVID-19), but there is a lack …

Objectives This study was designed to compare the efficacy and safety of
methylprednisolone and tocilizumab in the treatment of patients with severe COVID-19 …

The novel coronavirus disease 2019 (COVID-19) worldwide pandemic has placed a
significant burden on hospitals and healthcare providers. The immune response to this …